
## Piotr Jankowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/585713/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
2	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
3	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835.	1.8	558
4	Pulsatile but Not Steady Component of Blood Pressure Predicts Cardiovascular Events in Coronary Patients. Hypertension, 2008, 51, 848-855.	2.7	254
5	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis, 2019, 285, 135-146.	0.8	227
6	Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. European Heart Journal, 2017, 38, 2805-2812.	2.2	175
7	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. European Journal of Preventive Cardiology, 2021, 28, 370-379.	1.8	83
8	Effects of metabolic syndrome on arterial function in different age groups. Journal of Hypertension, 2018, 36, 824-833.	0.5	79
9	Heat Not Burn Tobacco Product—A New Global Trend: Impact of Heat-Not-Burn Tobacco Products on Public Health, a Systematic Review. International Journal of Environmental Research and Public Health, 2020, 17, 409.	2.6	79
10	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Archives of Medical Science, 2021, 17, 1447-1547.	0.9	78
11	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.9	70
12	The pulsatile component of blood pressure – Its role in the pathogenesis of atherosclerosis. Blood Pressure, 2007, 16, 238-245.	1.5	53
13	Relationship Between 24-Hour Ambulatory Central Systolic Blood Pressure and Left Ventricular Mass. Hypertension, 2017, 70, 1157-1164.	2.7	52
14	COVID-19 and cardiovascular complications – the preliminary results of the LATE-COVID study. Archives of Medical Science, 2021, 17, 818-822.	0.9	39
15	Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland. Archives of Medical Science, 2016, 4, 687-696.	0.9	37
16	Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. Journal of Clinical Lipidology, 2013, 7, 217-221.	1.5	28
17	Practice setting and secondary prevention of coronary artery disease. Archives of Medical Science, 2018, 14, 979-987.	0.9	27
18	Twenty-four-Hour Profile of Central Blood Pressure and Central-to-Peripheral Systolic Pressure Amplification. American Journal of Hypertension, 2013, 26, 27-33.	2.0	25

PIOTR JANKOWSKI

#	Article	IF	CITATIONS
19	Determinants of poor hypertension management in patients with ischaemic heart disease. Blood Pressure, 2005, 14, 284-292.	1.5	23
20	PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade. Archives of Medical Science, 2017, 4, 914-929.	0.9	22
21	Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry. European Journal of Preventive Cardiology, 2022, 29, 344-351.	1.8	22
22	Temporal trends in secondary prevention in myocardial infarction patients discharged with left ventricular systolic dysfunction in Poland. European Journal of Preventive Cardiology, 2018, 25, 960-969.	1.8	20
23	Impact of COVIDâ€19 pandemic on acute heart failure admissions and mortality: a multicentre study (COVâ€HFâ€6IRIO 6 study). ESC Heart Failure, 2022, 9, 721-728.	3.1	20
24	Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. Cardiology Journal, 2020, 27, 533-540.	1.2	18
25	Secondary prevention of coronary artery disease in contemporary clinical practice. Cardiology Journal, 2015, 22, 219-226.	1.2	17
26	Ascending aortic blood pressure waveform is related to coronary atherosclerosis in hypertensive as well as in normotensive subjects. Blood Pressure, 2007, 16, 246-253.	1.5	16
27	Relationship between Blood and Induced Sputum Eosinophils, Bronchial Hyperresponsiveness and Reversibility of Airway Obstruction in Mild-to-Moderate Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 354-361.	1.6	14
28	The challenge of blood pressure control in patients with ischaemic heart disease in Europe. Blood Pressure, 2005, 14, 6-9.	1.5	13
29	Twenty-Four–Hour Central (Aortic) Systolic Blood Pressure: Reference Values and Dipping Patterns in Untreated Individuals. Hypertension, 2022, 79, 251-260.	2.7	13
30	Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian Program for Secondary Prevention of Ischaemic Heart Disease. International Journal of Cardiology, 2003, 91, 15-23.	1.7	12
31	Clinical presentation and treatment of acute coronary syndrome as well as 1-year survival of patients hospitalized due to cancer. Medicine (United States), 2020, 99, e18972.	1.0	11
32	Managed Care after Acute Myocardial Infarction (MC-AMI) Reduces Total Mortality in 12-Month Follow-Up—Results from a Poland's National Health Fund Program of Comprehensive Post-MI Care—A Population-Wide Analysis. Journal of Clinical Medicine, 2020, 9, 3178.	2.4	9
33	Socioeconomic characteristics of patients with coronary heart disease in relation to their cardiovascular risk profile. Heart, 2021, 107, 799-806.	2.9	9
34	Polish Forum for Prevention Guidelines on Hypertension: update 2017. Kardiologia Polska, 2017, 75, 282-285.	0.6	9
35	Secondary prevention in patients after hospitalisation due to coronary artery disease: what has changed since 2006?. Kardiologia Polska, 2014, 72, 355-362.	0.6	9
36	Which patients at risk of cardiovascular disease might benefit the most from inclisiran? – The expert opinion of the Polish experts. The compromise between EBM and possibilities in healthcare Archives of Medical Science, 2022, 18, 569-576.	0.9	9

PIOTR JANKOWSKI

#	Article	IF	CITATIONS
37	Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey. Journal of Clinical Medicine, 2021, 10, 3711.	2.4	8
38	Palliative care for people living with cardiac disease. Kardiologia Polska, 2020, 78, 364-373.	0.6	8
39	Half of coronary patients are not instructed how to respond to symptoms of a heart attack. Cardiology Journal, 2011, 18, 668-674.	1.2	8
40	Age, sex, and secondary prevention of ischaemic heart disease in everyday practice. Kardiologia Polska, 2013, 71, 1251-1259.	0.6	8
41	Prevalence, diagnosis, and treatment of familial hypercholesterolaemia in outpatient practices in Poland. Kardiologia Polska, 2018, 76, 960-967.	0.6	8
42	Comprehensive coordinated care after myocardial infarction (KOS‑ZawaÅ,): a patient's perspective. Kardiologia Polska, 2019, 77, 568-570.	0.6	8
43	Cardiac Rehabilitation in Real Life. Medicine (United States), 2015, 94, e1257.	1.0	7
44	Hypercholesterolemia and prevention of cardiovascular diseases in the light of preventive medical examinations of employees in Poland. International Journal of Occupational Medicine and Environmental Health, 2019, 32, 865-872.	1.3	7
45	Polish Forum for Prevention Guidelines on Smoking: update 2017. Kardiologia Polska, 2017, 75, 409-411.	0.6	7
46	Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and III surveys. Kardiologia Polska, 2009, 67, 1353-9.	0.6	7
47	Do the Successive Waves of SARS-CoV-2, Vaccination Status and Place of Infection Influence the Clinical Picture and COVID-19 Severity among Patients with Persistent Clinical Symptoms? The Retrospective Study of Patients from the STOP-COVID Registry of the PoLoCOV-Study. Journal of Personalized Medicine, 2022, 12, 706.	2.5	7
48	Pulse Pressure, Blood Flow, and Atherosclerosis. American Journal of Hypertension, 2012, 25, 1040-1041.	2.0	6
49	Do we know more about hypertension in Poland after the May Measurement Month 2017?—Europe. European Heart Journal Supplements, 2019, 21, D97-D100.	0.1	6
50	Dietary measures among patients with coronary heart disease in Europe. ESC EORP Euroaspire V. International Journal of Cardiology, 2020, 302, 5-14.	1.7	6
51	Obesity in patients with established coronary artery disease over a 20-year period (1997–2017). Polish Archives of Internal Medicine, 2021, 131, 26-32.	0.4	6
52	Innovative Managed Care May Be Related to Improved Prognosis for Acute Myocardial Infarction Survivors. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007800.	2.2	6
53	The use of a mobile spirometry with a feedback quality assessment in primary care setting – A nationwide cross-sectional feasibility study. Respiratory Medicine, 2021, 184, 106472.	2.9	6
54	Factors related to the effectiveness of hypercholesterolemia treatment following hospitalization for coronary artery disease. Polish Archives of Internal Medicine, 2016, 126, 388-394.	0.4	6

#	Article	IF	CITATIONS
55	Neutrophil-to-Lymphocyte Ratio Is Not Associated with Severity of Coronary Artery Disease and Is Not Correlated with Vitamin D Level in Patients with a History of an Acute Coronary Syndrome. Biology, 2022, 11, 1001.	2.8	6
56	Treatment goal attainment for secondary prevention in coronary patients with or without diabetes mellitus – Polish multicenter study POLASPIRE. Archives of Medical Science, 2023, 19, 305-312.	0.9	5
57	Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , .	4.0	5
58	Serum Level of Vitamin D Is Associated with Severity of Coronary Atherosclerosis in Postmenopausal Women. Biology, 2021, 10, 1139.	2.8	5
59	May Measurement Month 2018: an analysis of blood pressure screening campaign results from Poland. European Heart Journal Supplements, 2020, 22, H108-H111.	0.1	4
60	Management of Dyslipidemia in Women and Men with Coronary Heart Disease: Results from POLASPIRE Study. Journal of Clinical Medicine, 2021, 10, 2594.	2.4	4
61	Longitudinal effects of a nurse-managed comprehensive cardiovascular disease prevention program for hospitalized coronary heart disease patients and primary care high-risk patients. Kardiologia Polska, 2020, 78, 429-437.	0.6	4
62	Vitamin D Level in Patients with Consecutive Acute Coronary Syndrome Is Not Correlated with the Parameters of Platelet Activity. Journal of Clinical Medicine, 2022, 11, 707.	2.4	4
63	Gender does not influence event-free survival in patients with ischaemic heart disease undergoing non-emergency coronary angiography. A single centre analysis. Kardiologia Polska, 2007, 65, 475-84; discussion 485.	0.6	4
64	Biochemical and cardiovascular predictors of PIMS-TS risk in children after COVID-19 recovery: preliminary results of the LATE-COVID-Kids Study. Archives of Medical Science, 2022, 18, 545-552.	0.9	4
65	Managed Care after Acute Myocardial Infarction (MC-AMI) improves prognosis in AMI survivors with pre-existing heart failure: A propensity score matching analysis of Polish nationwide program of comprehensive post-MI care. Kardiologia Polska, 2022, 80, 293-301.	0.6	4
66	Active screening for COPD among hospitalized smokers – a feasibility study. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232097111.	2.5	3
67	Smoking cessation in patients with established coronary artery disease: data from the POLASPIRE survey. Kardiologia Polska, 2021, 79, 418-425.	0.6	3
68	Mortality in patients after acute myocardial infarction managed by cardiologists and primary care physicians: a systematic review. Polish Archives of Internal Medicine, 2020, 130, 860-867.	0.4	3
69	BREAST cancer: tele- cardio- onco AID- a new concept for a coordinated care program (BREAST-AID) - rationale and study protocol. Polish Archives of Internal Medicine, 2019, 129, 295-298.	0.4	3
70	Renal denervation in patients with symptomatic chronic heart failure despite resynchronization therapy - a pilot study. Postepy W Kardiologii Interwencyjnej, 2019, 15, 240-246.	0.2	3
71	Small Differences in Vitamin D Levels between Male Cardiac Patients in Different Stages of Coronary Artery Disease. Journal of Clinical Medicine, 2022, 11, 779.	2.4	3
72	Effects of cardiac rehabilitation on risk factor management and quality of life in patients with ischemic heart disease: A multicenter cross-sectional study. Polish Archives of Internal Medicine, 2021, 131, 617-625.	0.4	2

PIOTR JANKOWSKI

#	Article	IF	CITATIONS
73	May Measurement Month 2019: an analysis of blood pressure screening results from Poland. European Heart Journal Supplements, 2021, 23, B124-B127.	0.1	2
74	Secondary prevention of coronary artery disease in hospital practice over the decade 1996-2006. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and EUROASPIRE III surveys. Kardiologia Polska, 2009, 67, 970-7.	0.6	2
75	Undiagnosed Diabetes and Prediabetes in Patients with Chronic Coronary Syndromes—An Alarming Public Health Issue. Journal of Clinical Medicine, 2021, 10, 1981.	2.4	1
76	Over time changes in the prevention of recurrent coronary artery disease in everyday practice. Polish Archives of Internal Medicine, 2021, 131, 673-678.	0.4	1
77	Dyslipidaemia, carbohydrate metabolism disorders and arterial hypertension detected in academic employees during examinations in occupational medicine. Annals of Agricultural and Environmental Medicine, 2021, 28, 314-318.	1.0	1
78	The use of direct immunofluorescence and nested polymerase chain reaction in diagnosing perinatal infections of Chlamydia trachomatis. Advances in Clinical and Experimental Medicine, 2018, 27, 1711-1716.	1.4	1
79	Temporal changes in the secondary prevention of coronary artery disease in patients following myocardial revascularization. Postepy W Kardiologii Interwencyjnej, 2020, 16, 422-428.	0.2	1
80	How drugs influencing central blood pressure prevent atherosclerosis complications?. Current Pharmaceutical Biotechnology, 2012, 13, 2449-55.	1.6	1
81	Recollection of Physician Information about Risk Factor and Lifestyle Changes in Chronic Coronary Syndrome Patients. International Journal of Environmental Research and Public Health, 2022, 19, 6416.	2.6	1
82	Delayed Diagnosis of Non-ST Segment Elevation Myocardial Infarction in a Young Patient with Multivessel Disease and Familial Hypercholesterolemia Complicated by Cardiogenic Shock Finally Treated with Intra-Aortic Balloon Pump as a Bridge to Extra Corporeal Membrane Oxygenation. Case Reports in Cardiology, 2019, 2019, 1-4.	0.2	0
83	The obesity pandemic among patients with coronary artery disease: do we have enough to tackle its progression? Authors' reply. Polish Archives of Internal Medicine, 2021, 131, 316-316.	0.4	Ο
84	Successful revascularization of total occlusion of the left anterior descending artery in patient with COVID-19 infection and treatment-resistant heart failure. Kardiologia Polska, 2021, 79, 889-890.	0.6	0
85	Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. Cardiology Journal, 2021, , .	1.2	0
86	Blood pressure and cholesterol control in the general population. Polish Archives of Internal Medicine, 2020, 130, 258-258.	0.4	0
87	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna I Wiadomości PTDL, 2021, 57, 1-99.	0.1	0
88	Lipid-lowering drugs and control of hypercholesterolemia in Poland: recent evidence. , 2011, 121, 164-71.		0